Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Advanced Cancer × FP-1039 × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 1 Advanced Cancer 1

Interventions

Nivolumab 6 Bevacizumab 5 temsirolimus 4 Sirolimus 4 Paclitaxel 4 Docetaxel 4 Pemetrexed 3 Ipilimumab 3 Erlotinib Hydrochloride 3 Carboplatin 3 ARRY-334543 3 apatinib 2 abemaciclib 2 Vorinostat 2 Sunitinib 2 Magnetic Resonance Spectroscopy 2 Gemcitabine 2 Everolimus 2 Chlorogenic Acid 2 Cetuximab 2 6-(6-(1-methyl-1H-pyrazol-4-yl)-(1,2,4)triazolo(4,3-b)pyridazin-3-ylsulfanyl)quinoline 2 vorolanib 1 vistusertib 1 trametinib 1 tislelizumab 1 tilsotolimod 1 sargramostim 1 regorafenib 1 ralimetinib 1 prexasertib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00687505 2021-12-13

Safety Study of FP-1039 To Treat Cancer

Five Prime Therapeutics, Inc.

Phase 1 Completed

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡